Bdparib 300mg Tablet
Rx RequiredSalt Composition: Rucaparib
Expiry Date: 01/2028
Price on Request
Inclusive of all taxes
60 Tablet in Bottle
About The Product
Ovarian Cancer, Prostate cancer
Bdparib 300mg tablet belongs to the class called polyADP-ribose polymerase inhibitors. It is an anti-cancer medicine, containing the active ingredient rucaparib. It is used for the treatment of primary peritoneal cancer (a layer of tissue that lines the abdomen), fallopian tube (present in females), and certain types of ovarian cancer. Bdparib 300mg tablet is also used to treat certain types of cancer in people with a specific gene (BRCA) change. This cancer medicine should be taken by individuals who are allergic to Bdparib or any of the ingredients.
Uses
Prostate cancer, Fallopian tube cancer, Ovarian cancer, primary peritoneal cancer.
Side Effects
- Undesired symptoms or responses vary from person to person as the human body reacts differently to the Bdparib 300 mg tablet.
- Still, they typically resolve naturally within a few days as the body adjusts to the medicine, requiring no medical attention.
- In case these symptoms don't go away and you face severe side effects, then immediately consult your doctor or medical team.
- Some of the common side effects of the Bdparib 300 mg tablet are: Headache, Fever Loss of appetite Pain in the eyes Blurred vision High blood pressure Dry skin lack of sleep.
- Vomiting Indigestion Nausea Reduced Kidney function, diarrhea, or constipation
How To Use
- Bdparib 300mg tablet is not a drug used for self-medication; it should always be taken as directed by a physician.
- As advised by the physician, it can be taken either with or without food.
- Your doctor will decide the dose and timing of the Bdparib 300 mg based on the disease condition and other factors.
- For best results in its effectiveness, the Bdparib 300mg tablet must be swallowed rather than chewed, opened, or crushed.
- It is an oral drug that is given once daily, before meals, at the same time every day.
- The Bdparib 300mg tablet should not be taken for at least three hours before or after food.
- Take it as prescribed by the physician.
How It Works
Bdparib 300mg tablet inhibits the enzyme that plays an important role in DNA repair, by inhibiting poly Adenosine diphosphate-ribose polymerase enzymes such as PARP-1, PARP-2, and PARP-3, which play a role in DNA repair. By blocking an enzyme associated with DNA repair, the spread of cancer cells can be stopped, resulting in their death.
Bdparib 300mg tablet does not allow damaged DNA to get repaired.
Safety Advice
Drinking too much alcohol could damage a person's immunity and liver function. Alcohol consumption can cause dizziness, confusion, tiredness, and cognitive impairment, so it is advised not to consume alcohol while taking the Bdparib 300mg tablet.
It is not advised to take the Bdparib 300mg tablet when pregnant because it affects the fetus. This is not for use in pregnant women.
Because there is a possibility that the Bdparib 300mg tablet could be transferred to the developing infant through the mother's breast milk, it is not advised to consume it while nursing. It is widely regarded as dangerous, and there is not enough evidence in the clinical data on its adverse impacts on infants.
Taking a BDPARIB 300mg tablet while operating machinery may cause confusion or affect one's capacity to drive. The capsule may cause neurological side effects, such as fever or feeling dizzy. Until you feel better, don't drive.
People with kidney issues can use the Bdparib 300mg tablet after consulting with the doctor. It may harm the kidneys if taken as self-medication
People with severe liver illness should not use the Bdparib 300mg tablet. Whereas people with mild liver disease can use this solution, but it must be regularly monitored. Use caution and alter the dosage of the Bdparib 300mg tablet as advised by your doctor.
FAQs
The doctor decides how long the treatment with the Bdparib 300mg tablet will continue, depending on the stage and health of the patient.
Reference
Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W.
W., Comber, H., & Bray, F. (2023).
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European journal of cancer, 49(6), 1374-1403.
Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., & Oza, A.
(2021). Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
The Lancet Oncology, 12(9), 852-861. Guo, X.
X., Wu, H. L., Shi, H.
Y., Su, L., & Zhang, X. (2025).
The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials. Cancer Management and Research, 2553-2562.
Pujade-Lauraine, E., Ledermann, J. A., Selle, F., Gebski, V., Penson, R.
T., Oza, A. M., & Vergote, I.
(2025). Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
The Lancet Oncology, 18(9), 1274-1284. Zhou, D., Li, J., Learoyd, M., Bui, K., Berges, A., Milenkova, T., & Xu, H.
(2024). Efficacy and safety exposure‐response analyses of olaparib capsule and tablet formulations in oncology patients.
Clinical Pharmacology & Therapeutics, 105(6), 1492-1500.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.png&w=48&q=75 "Cart"){kind=small}
9655.png&w=48&q=75 "Home"){kind=small}
